Growth hormone releasing peptide-6 (GHRP-6) ameliorates acute lung injury and its subsequent evolvement to interstitial fibrosis.

Animal study examining GHRP-6 effects on lung injury models

“We examined the ability of growth hormone releasing peptide 6 (GHRP-6) to attenuate the pulmonary damages associated with intratracheal instillation of LPS or ZYM combined injection with platelet activating factor (PAF) in mice.”

Mice

“We examined the ability of growth hormone releasing peptide 6 (GHRP-6) to attenuate the pulmonary damages associated with intratracheal instillation of LPS or ZYM combined injection with platelet activating factor (PAF) in mice.”

Acute scenarios evolved for 24 hours or 15 days; chronic scenarios terminated 28 days after intervention

“For the acute scenario, mice received LPS challenge and 6 h later, assigned to normal saline (Control) or to a single administration of each GHRP-6 dose and evolved for 24 h; or mice received four ZYM tracheal instillations and 6 h after, one PAF injection assigned to normal saline (Control) or to five administrations of each GHRP-6 dose and evolved for 15 days.”

GHRP-6 reduced neutrophilic alveolitis and attenuated lung compliance failure in the acute scenario

“The acute scenario, GHRP-6 reduced neutrophilic alveolitis, attenuated lung compliance failure, contributed to improve alveolar-capillary permeability, and reduced interleukin-1 beta serum levels.”

GHRP-6 preserved lung parenchymal integrity with meager collagen accumulation in the chronic scenario

“The chronic scenario, GHRP-6 preserved lung parenchymal integrity accounted for meager collagen accumulation.”